The Alzheimer's Association journal also published an earlier Anavex-Ariana collaboration (in 2020) called A precision medicine framework using artificial intelligence for the identification and confirmation of genomic biomarkers of response to an Alzheimer's disease therapy: Analysis of the blarcamesine (ANAVEX2-73) Phase 2a clinical study (https://alz-journals.onlinelibrary.wiley.com/doi/10.1002/trc2.12013).
Market Data 
Markets 
AI
